spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  sulfonylurea 

 HSMN NewsFeed - 30 Jul 2020
Jardiance(R) meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 27 Sep 2019
Currax(TM) Pharmaceuticals LLC Announces the Acquisition of Nalpropion Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 20 Sep 2019
CHMP Issues Positive Opinion to Expand Trulicity(R) (dulaglutide) Label to Include Results from REWIND Cardiovascular Outcomes Trial
Biopharmaceuticals Endocrinology Cardiology Regulatory
 HSMN NewsFeed - 26 Jun 2019
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 14 Feb 2019
Boehringer Ingelheim and Lilly announce the CAROLINA(R) cardiovascular outcome trial of Tradjenta(R) met its primary endpoint of non-inferiority compared with glimepiride
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 30 Oct 2018
U.S. FDA Approves INVOKANA(R) (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
Biopharmaceuticals Endocrinology Cardiology FDA
 HSMN NewsFeed - 26 Feb 2018
New Data Show Lilly's Trulicity(R) (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 10 Jan 2018
BYDUREON(R) BCise(TM) Injectable Medicine Now Available In The US For Patients With Type-2 Diabetes
Biopharmaceuticals Endocrinology Product Launch
 HSMN NewsFeed - 5 Dec 2017
INVOKANA(R) (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Potential Renal Protective Effects in Patients with Type 2 Diabetes Who Have or Are at Risk for Cardiovascular Disease
Biopharmaceuticals Nephrology
 HSMN NewsFeed - 5 Jan 2017
Eisai Acquires All Global Development And Marketing Rights For Chronic Weight Management Treatment Lorcaserin HCI
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 8 Nov 2016
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant for Contrave(R) (naltrexone HCl / bupropion HCl extended release) in Australia and New Zealand
Biopharmaceuticals Distribution
 HSMN NewsFeed - 21 Sep 2016
U.S. FDA Approves INVOKAMET(R) XR (Canagliflozin / Metformin Hydrochloride Extended-Release) for the Treatment of Adults with Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 29 Jun 2016
FDA Advisory Committee recommends approval of Jardiance(R) (empagliflozin) for cardiovascular indication in 12-11 vote
Biopharmaceuticals Endocrinology Cardiology FDA
 HSMN NewsFeed - 8 Jun 2016
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 15 Mar 2016
Orexigen and Takeda Jointly Announce Orexigen's Acquisition of All Rights to CONTRAVE(R) in the United States
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 20 Aug 2015
Jardiance(R) Demonstrated Cardiovascular (CV) Risk Reduction in People with Type 2 Diabetes at High Risk for CV Events
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 30 Oct 2014
U.S. FDA Approves Once-Daily XIGDUO(TM) XR Tablets for Adults with Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 8 Apr 2014
Takeda Responds to Verdict in Diabetes Drug Case
Biopharmaceuticals Endocrinology Litigation
 HSMN NewsFeed - 3 Mar 2014
U.S. FDA Approves Bydureon(R) Pen (exenatide extended-release for injectable suspension) for Once-Weekly Treatment of Adults with Type 2 Diabetes
Biopharmaceuticals Drug Delivery Endocrinology FDA
 HSMN NewsFeed - 19 Jun 2013
AstraZeneca and Bristol-Myers Squibb Announce Top Line Results for SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza(R) (saxagliptin)
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 7 Jun 2013
Eisai Announces Availability of BELVIQ(R) (lorcaserin HCl) CIV Tablets for Chronic Weight Management in Adults who are Overweight with a Comorbidity or Obese
Biopharmaceuticals
 HSMN NewsFeed - 29 Apr 2013
Merck & Co., Inc. and Pfizer Enter Worldwide Collaboration Agreement to Develop and Commercialize Ertugliflozin, an Investigational Medicine for Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 23 Mar 2012
BYETTA(R) Approved for Use with Basal Insulin in Europe
Biopharmaceuticals Endocrinology Regulatory
 HSMN NewsFeed - 8 Nov 2011
Lilly and Amylin Mutually Agree to End Diabetes Alliance and Transition Exenatide Responsibility to Amylin
Biopharmaceuticals
 HSMN NewsFeed - 21 Jun 2011
Bydureon Receives Marketing Authorization in Europe
Biopharmaceuticals Endocrinology Regulatory
 HSMN NewsFeed - 16 May 2011
Lilly Provides Its Perspective in Response to Amylin Lawsuit
Biopharmaceuticals Litigation
 HSMN NewsFeed - 16 May 2011
Lilly Provides Statement in Response to Amylin Lawsuit
Biopharmaceuticals Litigation
 HSMN NewsFeed - 16 May 2011
Amylin Pharmaceuticals Files Suit Against Eli Lilly
Biopharmaceuticals Litigation
 HSMN NewsFeed - 21 Apr 2011
Novo Nordisk Announces U.S. Launch of NovoTwist(R) for Use with Levemir(R) FlexPen(R), NovoLog(R) FlexPen(R) and Victoza(R) Pen Devices
Devices Drug Delivery Endocrinology
 HSMN NewsFeed - 15 Apr 2011
BYDUREON Recommended for Approval in Europe
Biopharmaceuticals Endocrinology Regulatory
 HSMN NewsFeed - 15 Nov 2010
Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 23 Sep 2010
Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S.
Biopharmaceuticals Endocrinology Regulatory
 HSMN NewsFeed - 28 Apr 2010
Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S.
Biopharmaceuticals Litigation Endocrinology
 HSMN NewsFeed - 15 Mar 2010
Amylin, Lilly and Alkermes Receive Complete Response Letter From FDA for Exenatide Once Weekly Submission
Biopharmaceuticals
 HSMN NewsFeed - 9 Mar 2010
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (SAVOR-TIMI 53)
Biopharmaceuticals Cardiology Endocrinology
 HSMN NewsFeed - 24 Feb 2010
GlaxoSmithKline Responds to US Senate Committee on Finance Report on Avandia
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 26 Jan 2010
Novo Nordisk's Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 29 Sep 2009
Boehringer Ingelheim's Diabetes Pipeline Continues to Advance as the Company Announces Conclusion of Robust Phase III Clinical Program for linagliptin
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 29 Apr 2009
Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 23 Apr 2009
U.S. Food and Drug Administration Extends Review Timeline for ONGLYZA (saxagliptin) New Drug Application
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 26 Mar 2009
Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 23 Jul 2008
Bristol-Myers Squibb and AstraZeneca Submit New Drug Application in the United States and Marketing Authorization Application in Europe for ONGLYZA(TM) (saxagliptin) for the Treatment of Type 2 Diabetes
Biopharmaceuticals FDA Endocrinology
 HSMN NewsFeed - 22 Jul 2008
Santarus and Depomed Announce U.S. Promotion Agreement for GLUMETZA Prescription Products
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 14 Jul 2008
FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 16 May 2008
Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 24 Apr 2008
Two Merck Medicines Recommended for Approval in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 31 Mar 2008
New Data Showed ACTOS(R) (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes
Biopharmaceuticals Cardiology Endocrinology
 HSMN NewsFeed - 21 Feb 2008
Lilly Launches KwikPen(TM) for Humalog(R) and Humalog Mixtures
Biopharmaceuticals Drug Delivery Endocrinology
 HSMN NewsFeed - 21 Jan 2008
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults With Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 19 Jan 2008
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 14 Jan 2008
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
Biopharmaceuticals Endocrinology Generics FDA
 HSMN NewsFeed - 2 Jan 2008
Depomed Receives FDA Approval for 1000 mg Strength Tablets of Glumetza
Biopharmaceuticals FDA Endocrinology Drug Delivery
 HSMN NewsFeed - 11 Dec 2007
GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 6 Dec 2007
Monotherapy BYETTA(R) Showed Significant Improvement in Glucose Control and Weight Loss in Adults with Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 19 Nov 2007
Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 14 Nov 2007
GSK Revises US Labeling for Avandia(R)
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 29 Oct 2007
Depomed and King Pharmaceuticals Terminate Promotion Agreement for GLUMETZA(TM)
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 17 Oct 2007
FDA Approves Supplemental New Drug Applications for JANUVIA(TM) (sitagliptin)
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 21 Sep 2007
One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 19 Sep 2007
ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients With Type 2 Diabetes
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 18 Sep 2007
New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 11 Sep 2007
Takeda Statement on ACTOS(R) (pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 11 Sep 2007
GlaxoSmithKline Responds to JAMA Articles
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 24 Jun 2007
New Data Show Patients Treated With Avandia(R) (Rosiglitazone Maleate) Incurred Lower Medical Costs and Used Fewer Healthcare Resources When Compared to Patients Treated With Sulphonylureas
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 24 Jun 2007
BYETTA(R) Study Showed Comparable Blood Glucose Control to Insulin
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 23 Jun 2007
Results of Two Head-to-Head Studies Demonstrated Long-Acting Insulin Lantus(R) Lowered Free Fatty Acid Levels Equal to or Better Than Thiazolidinediones
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 23 Jun 2007
BYETTA(R) Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 6 Jun 2007
Takeda Revises ACTOS(R) (pioglitazone HCl) Prescribing Label
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 6 Jun 2007
Statement of Moncef Slaoui, PhD, Chairman Research & Development GlaxoSmithKline
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 6 Jun 2007
Newly Published Data From Large Study Support Cardiovascular Safety of Avandia (rosiglitazone maleate)
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 30 May 2007
Data Affirms Avandia (Rosiglitazone maleate) Cardiovascular Safety Profile
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 21 May 2007
GlaxoSmithKline Responds to NEJM Article on Avandia
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 2 Apr 2007
FDA Approves JANUMET(TM) for Type 2 Diabetes, Offering Powerful Glucose Control of a DPP-4 Inhibitor and Metformin in a Single Tablet
Biopharmaceuticals FDA Endocrinology
 HSMN NewsFeed - 2 Apr 2007
Depomed Files Prior Approval Supplement for 1000 mg Strength Tablets of Glumetza
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 22 Feb 2007
Lilly Introduces World's First Digital Insulin Pen With Memory
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 20 Feb 2007
New Storage Instructions Approved for BYETTA(R)
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 15 Feb 2007
FDA Accepts Two Supplemental New Drug Applications to Expand the U.S. Labeling for JANUVIA(TM)
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 19 Jan 2007
Barr Launches Generic METAGLIP(TM) Tablets, 2.5/250 mg, 2.5/500 mg and 5/500 mg
Biopharmaceuticals Generics Endocrinology
 HSMN NewsFeed - 3 Jan 2007
FDA Approves BYETTA(R) (exenatide) Injection for Expanded Combination Use
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 22 Dec 2006
FDA Approves BYETTA(R) (exenatide) Injection for Expanded Combination Use
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 4 Dec 2006
Landmark Study Shows Avandia(R) (rosiglitazone maleate) Is More Effective Than Metformin or a Sulfonylurea in Long-Term Blood Sugar Control in Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 21 Nov 2006
BYETTA(R) (exenatide) Approved for Treatment of Type 2 Diabetes by European Commission
Biopharmaceuticals Endocrinology Regulatory
 HSMN NewsFeed - 13 Nov 2006
New Data Show ACTOS(R) (pioglitazone HCl) Halted Progression of Atherosclerosis as Indicated by CIMT in Patients With Type 2 Diabetes
Biopharmaceuticals
 HSMN NewsFeed - 21 Sep 2006
Exenatide Receives Positive Opinion From the European Committee for Medicinal Products for Human Use for the Treatment of Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 14 Sep 2006
Study Shows Exenatide Improves Blood Sugar Levels as Effectively as Biphasic Insulin Aspart
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 14 Sep 2006
ACTOS(R) (pioglitazone HCl) Demonstrates Significant Improvements in Cardiovascular Outcomes for High-Risk Patients With Type 2 Diabetes
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 7 Sep 2006
SYMLIN Improved Diabetes Control in Patients With Type 2 Diabetes on Established Regimens of Basal Insulin
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 28 Jun 2006
King Pharmaceuticals and Depomed Announce Agreement to Co-Promote Glumetza(TM)
Biopharmaceuticals Endocrinology
Return to NewsFeed  

 Additional items found! 63

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 63 additional stories matching:
sulfonylurea
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!